Shares of biotechnology company Jasper Therapeutics (NASDAQ:JSPR) have put on triple-digit gains today after it announced positive data in the first three subjects (suffering from sickle cell disease and beta-thalassemia) of the Phase1/2 trial evaluating the addition of briquilimab to an existing regimen of bone marrow transplantation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The addition of the anti-c-KIT monoclonal antibody is being evaluated as a possible way to reach a higher level of donor chimerism without increasing toxicity.
In the trial, all the subjects successfully engrafted, and importantly there were no adverse events associated with briquilimab.
But there’s more, the first two subjects “with peripheral blood chimerism achieved 100% donor myeloid chimerism at 60 days post-transplant.”
The promising results have propelled JSPR shares over 200% today. Despite this rise, the stock price is still down nearly 76% over the past year.
Oppenheimer’s Jay Olson though has a Buy rating on the stock and a price target of $8. This points to a further 292% potential upside in the stock.
Read full Disclosure